Comparative Effectiveness Trial of Transoral Head and Neck Surgery Followed by Adjuvant Radio(Chemo)Therapy Versus Primary Radiochemotherapy for Oropharyngeal Cancer

Exclusion Criteria

• •Prior invasive malignancy except controlled skin cancer or carcinoma in situ of cervix
• •Unknown primary (CUP), nasopharynx, hypopharynx, laryngeal or salivary gland cancer
• •Metastatic disease
• •Serious co-morbidity, e.g. high-grade carotid artery stenosis, congestive heart failure NYHA grade 3 and 4, liver cirrhosis CHILD C
• •Hemoglobin level \<9.5g/dl within 4 weeks before randomization
• •Pregnancy or lactation
• •Women of child-bearing potential with unclear contraception
• •Previous treatment with chemotherapy, radiotherapy, EGFR-targeting agents or surgery exceeding biopsy in head and neck
• •Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational drug within 30 days prior to study screening
• •Social situations that limit compliance with study requirements or patients with an unstable condition (e.g., psychiatric disorder, a recent history of drug or alcohol abuse, interfering with study compliance, within 6 months prior to screening) or otherwise thought to be unreliable or incapable of complying with the requirements of the protocol
• •Patients institutionalized by official means or court order
• •Deficient